MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...

The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...

The FDA approved Exact Sciences’ Cologuard Plus multitarget stool DNA test to screen adults aged 45 years or older at average risk for colorectal cancer, according to a company press release. Compared ...

The Food and Drug Administration (FDA) has approved the Cologuard Plus™ test for colorectal cancer screening in adults aged 45 years and older who are at average risk for colorectal cancer. According ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ...

Kam knew it was important to get screened for colon cancer as soon as she was eligible. With her dad’s side of the family being affected by breast, kidney and prostate cancer, Kam wanted to “get all ...

(NEXSTAR) — An unexpected delivery at your door may not always be an unwelcome surprise — just ask one Kentucky boy about the thousands of dollars worth of lollipops that arrived at his home earlier ...

Colorectal Cancer Awareness Month is observed every year during March and aims to promote screening and early detection, raise awareness, and offer support to those battling the disease. Since March ...

Colorectal Cancer Awareness Month is observed annually in March and aims to promote screening and early detection, raise awareness, and offer support to those battling the disease. As it has done ...

Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize ...